Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Int J Urol Retrieve available abstracts of 210 articles: HTML format

Single Articles

August 2026
1. HATANO K, Watabe T, Hirata T, Konishi M, et al
   [(18)F]PSMA-1007 PET-Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer.
   Int J Urol. 2026;33:e70587.
   PubMed     Abstract available
   
   
   
2. SEKKELI S, Erbin A, Erdal FS, Gursoy E, et al
   The Impact of Dutasteride Treatment on Subsequent Multiparametric Prostate Magnetic Resonance Imaging Sequences and PI-RADS Score in Patients With PI-RADS 3 Lesions in the Transitional Zone.
   Int J Urol. 2026;33:e70585.
   PubMed     Abstract available
   
   
   
3. FUJIWARA M, Fujikawa A, Aso S, Zaizen T, et al
   Transverse Versus Vertical Camera Port Incision for Patient Satisfaction After Robot-Assisted Radical Prostatectomy.
   Int J Urol. 2026;33:e70593.
   PubMed     Abstract available
   
   
   
4. YASUDA Y, Yoshida S, Yonese I, Sano Y, et al
   Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.
   Int J Urol. 2026;33:e70590.
   PubMed     Abstract available
   
   
   
5. ABE K, Miyazawa Y, Nakazawa S, Onose M, et al
   Real-World Outcomes of Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation.
   Int J Urol. 2026;33:e70591.
   PubMed     Abstract available
   
   
   
6. KAMIYAMA M, Izumi K, Mitsui T, Shima T, et al
   Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.
   Int J Urol. 2026;33:e70599.
   PubMed     Abstract available
   
   
   
7. NAKAI Y
   Editorial Comment on "Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization".
   Int J Urol. 2026;33:e70605.
   PubMed    
   
   
   
8. SUGIHARA N, Sawada T, Arai H, Nishida K, et al
   Clinical Outcomes of Single-Dose Flomoxef Prophylaxis for Transrectal Prostate Biopsy: A Single-Center Study of 834 Cases.
   Int J Urol. 2026;33:e70595.
   PubMed     Abstract available
   
   
   
9. OONO T, Terashita M, Mori S, Oka A, et al
   Validation of the NCCN Subclassification for Intermediate-Risk Prostate Cancer in a Japanese Radical Prostatectomy Cohort: Results From the MICAN Study.
   Int J Urol. 2026;33:e70592.
   PubMed     Abstract available
   
   
   
10. FUJITA K, Makita A, Ishii D, Yamamoto H, et al
    Perioperative Outcomes of Salvage Radical Prostatectomy After Radiation Therapy: A Nationwide Analysis Using the National Clinical Database of Japan.
    Int J Urol. 2026;33:e70602.
    PubMed     Abstract available
    
    
    
11. IWAMOTO H, Izumi K, Hori T, Inaba T, et al
    Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis.
    Int J Urol. 2026;33:e70603.
    PubMed     Abstract available
    
    
    July 2026
12. ELTING L, Almohtasib J, Francisco IFS, Perez-Londono A, et al
    Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.
    Int J Urol. 2026;33:e70568.
    PubMed     Abstract available
    
    
    
13. SAKAMOTO S, Yamamoto K, Yamamoto H, Hatakeyama S, et al
    A Nationwide Descriptive Analysis of Real-World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database.
    Int J Urol. 2026;33:e70567.
    PubMed     Abstract available
    
    
    
14. MATSUO T, Ozawa Y, Yorozu A, Hattori S, et al
    Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization.
    Int J Urol. 2026;33:e70574.
    PubMed     Abstract available
    
    
    
15. HATA K, Goto Y, Hashimoto M, Okamoto M, et al
    Bleeding Events Associated With Continuing Antithrombotic Therapy During Transrectal Ultrasound-Guided Prostate Biopsy: A Propensity Score-Matched Analysis.
    Int J Urol. 2026;33:e70580.
    PubMed     Abstract available
    
    
    
16. MITA Y, Teishima J, Ueki H, Wakita N, et al
    Effects of Modifying Hinotori Surgical Robot System on the Learning Curve of Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70577.
    PubMed     Abstract available
    
    
    
17. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial.
    Int J Urol. 2026;33:e70582.
    PubMed     Abstract available
    
    
    June 2026
18. ANDO S, Del Aguila Moraga DA, Hoshina H, Kawahira H, et al
    Artificial Intelligence-Based Objective Evaluation of Nerve-Sparing Status Combined With Preserved Urethral Length Predicts Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70514.
    PubMed     Abstract available
    
    
    
19. SUZUKI T, Fukuda T, Nishizaki K, Fukui K, et al
    Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.
    Int J Urol. 2026;33:e70533.
    PubMed     Abstract available
    
    
    
20. HAGIMOTO H, Kubota M, Mizuno K, Sumiyoshi T, et al
    Younger Age Is Associated With Early Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70535.
    PubMed     Abstract available
    
    
    
21. TOHI Y, Merseburger AS, Sugimoto M
    Editorial Comment on to Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.
    Int J Urol. 2026;33:e70440.
    PubMed    
    
    
    May 2026
22. MIYAZAWA Y
    Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup
    Int J Urol. 2026;33:e70488.
    PubMed    
    
    
    
23. KANAKI T, Hatano K, Oka T, Tani M, et al
    Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    Int J Urol. 2026;33:e70476.
    PubMed     Abstract available
    
    
    
24. GORDON N, Patel AA, Farooq W, Watson W, et al
    Gleason Regrading After Prostatectomy-Results From the Irish Prostate Cancer Outcome Research (IPCOR) Situated in the International Context.
    Int J Urol. 2026;33:e70469.
    PubMed     Abstract available
    
    
    
25. KYODA Y, Hori M, Nakanishi M, Shindo T, et al
    Impact of Hormonal and Radiation Therapy on Bladder Outlet Obstruction in High-Risk Localized Prostate Cancer: A Prospective Pressure-Flow Study.
    Int J Urol. 2026;33:e70502.
    PubMed     Abstract available
    
    
    
26. HOSHI S, Izumi K, Meguro S, Shima T, et al
    Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.
    Int J Urol. 2026;33:e70511.
    PubMed     Abstract available
    
    
    
27. KASHIWAGI E, Ushijima M, Ueda S, Tsubonuma Y, et al
    Reduced Uncoupling Protein 1 Expression in Periprostatic Adipose Tissue and Its Association With Higher Prostate Cancer Grade.
    Int J Urol. 2026;33:e70506.
    PubMed     Abstract available
    
    
    April 2026
28. SATO Y, Fujii Y, Kume H
    Cancer Genomic Medicine for Urological Malignancies in Japan.
    Int J Urol. 2026;33:e70449.
    PubMed     Abstract available
    
    
    
29. TAKAHASHI S
    Editorial Comment to Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low- and Intermediate-Risk Localized Prostate Cancer.
    Int J Urol. 2026;33:e70457.
    PubMed    
    
    
    
30. HONDA K, Oka S, Makiyama K, Tatenuma T, et al
    Artificial Intelligence-Based Recognition of the Prostatic Capsule During Nerve-Sparing Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70454.
    PubMed     Abstract available
    
    
    
31. AKAGI N, Nagoshi A, Kubota M, Hagimoto H, et al
    Hemorrhagic Risk of Transrectal Ultrasound-Guided Prostate Biopsy Under Continued Antithrombotic Therapy.
    Int J Urol. 2026;33:e70462.
    PubMed     Abstract available
    
    
    
32. HARA T, Matsumoto K, Nirazuka A, Kanehira M, et al
    Nationwide Real-World Outcomes of Robot-Assisted Radical Prostatectomy Using the Hinotori Surgical Robot System in Japan.
    Int J Urol. 2026;33:e70460.
    PubMed     Abstract available
    
    
    
33. NAKANISHI Y, Okumura G, Ikezoe E, Gozu S, et al
    Impact of Preoperative Diagnosis of Overactive Bladder and Intravesical Prostatic Protrusion on Postoperative Overactive Bladder Symptom Improvement Following Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70470.
    PubMed     Abstract available
    
    
    
34. YE D, Saad M, Lee JY, Jung W, et al
    Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE St
    Int J Urol. 2026;33:e70455.
    PubMed     Abstract available
    
    
    March 2026
35. IIDA K, Hayashi Y, Narita K, Itami Y, et al
    Clinical Outcomes of Hypofractionated Radiotherapy With 12 Fraction for Low- and Intermediate-Risk Localized Prostate Cancer.
    Int J Urol. 2026;33:e70391.
    PubMed     Abstract available
    
    
    
36. KOYAMA Y, Morizane S, Moriyasu E, Hoshino T, et al
    Effect of Neoadjuvant Chemo-Hormonal Therapy on Reducing Recurrence in Patients With Very High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70387.
    PubMed     Abstract available
    
    
    
37. UCHIDA K, Watanabe H, Matsushita Y, Tamura K, et al
    Robot-Assisted Radical Cystectomy Using the Hinotori Surgical System in Patients With Previous Prostate Cancer Treatment: A Single-Institution Case Series.
    Int J Urol. 2026;33:e70383.
    PubMed    
    
    
    
38. HIBINO T, Kato M, Tsuzuki T, Nishikimi T, et al
    Total Positive Margin Length as a Novel Prognostic Indicator After Radical Prostatectomy.
    Int J Urol. 2026;33:e70395.
    PubMed     Abstract available
    
    
    
39. SUGINO A, Miyazawa Y, Nakazawa S, Tsuji Y, et al
    Active Surveillance for Localized Prostate Cancer: A Retrospective Single-Center Study.
    Int J Urol. 2026;33:e70433.
    PubMed     Abstract available
    
    
    
40. YAEGASHI H, Nakashima K, Miwa S, Miyagi T, et al
    Clinical Validation of the Prostate Health Index for Detecting Clinically Significant Prostate Cancer in a Population-Based Screening Program.
    Int J Urol. 2026;33:e70409.
    PubMed     Abstract available
    
    
    
41. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Significance of Radiographic Progression at Metastatic Castration-Resistant Prostate Cancer Diagnosis.
    Int J Urol. 2026;33:e70435.
    PubMed     Abstract available
    
    
    
42. KAZASHI K, Washino S, Saito K, Oshiro H, et al
    Functional and Oncological Outcomes of Novel Anterior, Retzius-Sparing, and Conventional Anterior Approaches in Robot-Assisted Radical Prostatectomy: A Comparative Cohort Study.
    Int J Urol. 2026;33:e70412.
    PubMed     Abstract available
    
    
    February 2026
43. HATAKEYAMA S, Yoneyama T, Ohyama C
    Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.
    Int J Urol. 2026;33:e70371.
    PubMed     Abstract available
    
    
    
44. SASAKI T, Igarashi A, Ebara S, Tatenuma T, et al
    Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).
    Int J Urol. 2026;33:e70370.
    PubMed     Abstract available
    
    
    
45. MIURA N, Shimbo M, Shishido K, Nobumori S, et al
    Impact of the 2025 NCCN Definition Change for Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy: A Retrospective Cohort.
    Int J Urol. 2026;33:e70366.
    PubMed     Abstract available
    
    
    
46. UMEMORI M, Urabe F, Iwamoto Y, Imai Y, et al
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70368.
    PubMed     Abstract available
    
    
    
47. TAKAHARA K, Takeuchi A, Saruta M, Yoshizawa A, et al
    Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current Evidence and Future Directions.
    Int J Urol. 2026;33:e70375.
    PubMed     Abstract available
    
    
    
48. DAGLI I, Canbolat MZ, Uzel T, Cayirli A, et al
    Local Anesthetic Transperineal Prostate Biopsy: Does It Affect Uroflowmetry Results.
    Int J Urol. 2026;33:e70377.
    PubMed     Abstract available
    
    
    
49. CHEN W, Yoshida S, Yajima S, Tanabe K, et al
    Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed Individual Patient Data From the PEACE-3 Trial.
    Int J Urol. 2026;33:e70376.
    PubMed     Abstract available
    
    
    
50. KOBAYASHI S, Shiota M, Onozawa M, Taguchi S, et al
    To Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.
    Int J Urol. 2026;33:e70381.
    PubMed     Abstract available
    
    
    
51. TANABE K, Yoshida S, Chen W, Yajima S, et al
    Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup Results.
    Int J Urol. 2026;33:e70384.
    PubMed     Abstract available
    
    
    
52. TAKAHASHI H, Fukuokaya W, Muramoto K, Katsumi K, et al
    Real-World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70369.
    PubMed     Abstract available
    
    
    January 2026
53. TAMADA T, Takeuchi M, Moriya K, Ueda Y, et al
    The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management.
    Int J Urol. 2026 Jan 7. doi: 10.1111/iju.70338.
    PubMed     Abstract available
    
    
    
54. ALKAN VURGUN N, Sen Turk N, Vurgun S, Yagci AB, et al
    Risk-Stratified Gleason Upgrading in ISUP Grade Group 1 Prostate Cancer: Combined Analysis of TMPRSS2-ERG, PTEN, Ki-67, and MRI-Derived Apparent Diffusion Coefficient Values.
    Int J Urol. 2026;33:e70346.
    PubMed     Abstract available
    
    
    
55. MASUDA N, Hazama T, Hosomi T, Imai K, et al
    Technique Selection for Robot-Assisted Radical Prostatectomy: A Multi-Institutional Survey in Japan.
    Int J Urol. 2026;33:e70347.
    PubMed     Abstract available
    
    
    
56. UENO Y
    Editorial Comment on "The Evolution of Prostate Multiparametric MRI and Its Application in Prostate Cancer Clinical Management".
    Int J Urol. 2026;33:e70353.
    PubMed    
    
    
    
57. KAR F
    Editorial Comment on (Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer).
    Int J Urol. 2026;33:e70352.
    PubMed    
    
    
    
58. MASSOUH K, Leucht K, Leistritz L, Grimm MO, et al
    Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without Radiotherapy.
    Int J Urol. 2026;33:e70339.
    PubMed     Abstract available
    
    
    
59. SUZUKI Y, Sonobe S, Kawasaki Y, Ikumi S, et al
    Operative Time Prediction by Machine Learning for Robot-Assisted Laparoscopic Radical Prostatectomy.
    Int J Urol. 2026;33:e70292.
    PubMed     Abstract available
    
    
    
60. TANAKA H, Kobayashi M, Matsumoto S, Ishikawa Y, et al
    Impact of Approach Routes in MRI-Ultrasound Fusion Prostate Biopsy on Post-Biopsy Complications: A Propensity Score-Matched Analysis.
    Int J Urol. 2026;33:e70275.
    PubMed     Abstract available
    
    
    
61. MAKABE S, Hata J, Tsumori T, Hiraguri A, et al
    Abdominal Subcutaneous Fat Thickness Is a Useful Predictor for Lower Urinary Tract Dysfunction After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70249.
    PubMed     Abstract available
    
    
    
62. ISHII N, Yoneyama T, Minakawa S, Konishi S, et al
    Immediate Postoperative cfDNA Elevation Predicts Pain After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70297.
    PubMed     Abstract available
    
    
    
63. MONCADA I, Krishnappa P, Fraile-Poblador A, Moscatiello P, et al
    A Comparative Study of Simultaneous and Delayed Penile Prosthesis During Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2026;33:e70285.
    PubMed     Abstract available
    
    
    December 2025
64. FUKIAGE Y, Taga M, Inamura M, Kaeriyama K, et al
    Magnetic Resonance Imaging-Transrectal Ultrasound Fusion-Targeted Biopsy Improves the Diagnostic Efficacy of Overall and Clinically Significant Prostate Cancer.
    Int J Urol. 2025 Dec 26. doi: 10.1111/iju.70334.
    PubMed     Abstract available
    
    
    
65. HAGIMOTO H, Sakamoto S, Sato K, Nakamura K, et al
    Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70326.
    PubMed     Abstract available
    
    
    
66. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    PubMed     Abstract available
    
    
    
67. KOKETSU Y, Iwamoto H, Hiratsuka K, Inaba T, et al
    Whole-Blood RNA Expression of Immunosuppressive Cell-Related Genes Is Associated With Prostate Cancer Progression.
    Int J Urol. 2025 Dec 21. doi: 10.1111/iju.70323.
    PubMed     Abstract available
    
    
    
68. WATANABE R
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Dec 10. doi: 10.1111/iju.70317.
    PubMed    
    
    
    
69. URABE F
    Editorial Comment on "DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade".
    Int J Urol. 2025 Dec 8. doi: 10.1111/iju.70311.
    PubMed    
    
    
    
70. BASARAN E, Hacioglu C
    Abiraterone Acetate Triggers ER Stress-Mediated Androgen Receptor Suppression via PERK/ATF4/CHOP Signaling in Prostate Cancer.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70304.
    PubMed     Abstract available
    
    
    
71. MITSUNARI K, Nakamura Y, Imamura R
    Editorial Comments on the Preliminary Analysis of Prostate Cancer Screening Results and Exploration of a Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Dec 3. doi: 10.1111/iju.70308.
    PubMed    
    
    
    
72. OKAMOTO K, Ozawa Y, Kayaba T, Koike S, et al
    Does Accessory Pudendal Artery Preservation Increase the Risk of Positive Surgical Margins in Robot-Assisted Radical Prostatectomy?
    Int J Urol. 2025;32:1762-1770.
    PubMed     Abstract available
    
    
    November 2025
73. SAKO S, Ito S, Ueda T, Gabata Y, et al
    DNA Methylation Levels at the C3orf37 Loci Correlate With Prostate Cancer Grade.
    Int J Urol. 2025 Nov 27. doi: 10.1111/iju.70299.
    PubMed     Abstract available
    
    
    
74. FANG D, Bi S, Wu L, Wang C, et al
    Preliminary Analysis of Prostate Cancer Screening Results and Exploration of Screening Model for Elderly Males in Rural Areas of Songjiang District, Shanghai.
    Int J Urol. 2025 Nov 21. doi: 10.1111/iju.70274.
    PubMed     Abstract available
    
    
    
75. HASHIZUME A
    Editorial Comment on Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Nov 17. doi: 10.1111/iju.70262.
    PubMed    
    
    
    
76. KANEKO G
    Editorial Comment to "Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study".
    Int J Urol. 2025 Nov 4. doi: 10.1111/iju.70278.
    PubMed    
    
    
    
77. NISHINO T, Shimbo M, Sano M, Oguchi T, et al
    Incidence, Risk Factors, and Clinical Characteristics of Late Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1688-1695.
    PubMed     Abstract available
    
    
    
78. KOHADA Y, Kitano H, Tasaka S, Ono Y, et al
    Association Between Preoperative Penile Circumference and Urinary Function After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1576-1586.
    PubMed     Abstract available
    
    
    
79. NAKAMURA M, Muraki Y, Yamada Y, Matsumoto S, et al
    Impact of Enhanced Recovery After Surgery Protocol on Perioperative Quality of Life in Robot-Assisted Radical Prostatectomy: A Single-Center Prospective Cohort Study.
    Int J Urol. 2025;32:1561-1568.
    PubMed     Abstract available
    
    
    October 2025
80. AIZAWA R, Mizowaki T
    Editorial Comment on "Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer".
    Int J Urol. 2025 Oct 29. doi: 10.1111/iju.70272.
    PubMed    
    
    
    
81. URABE F
    Editorial Comment on Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 26. doi: 10.1111/iju.70269.
    PubMed    
    
    
    
82. KAWAHARA T
    Re: Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70259.
    PubMed    
    
    
    
83. ALANBUKI A
    Editorial Comment: Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70264.
    PubMed    
    
    
    
84. YAJIMA S, Yoshida S, Fukushima H, Hirakawa A, et al
    Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the ARCHES Trial.
    Int J Urol. 2025 Oct 12. doi: 10.1111/iju.70256.
    PubMed    
    
    
    
85. SUZUKI K, Khan N, Taguchi T, Hattori K, et al
    Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
    PubMed     Abstract available
    
    
    
86. SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al
    Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
    PubMed    
    
    
    
87. YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al
    Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
    PubMed    
    
    
    
88. ESCANDE R, Jaouen T, Gonindard-Melodelima C, Crouzet S, et al
    External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System Aimed at Characterizing ISUP >/= 2 Prostate Cancers at Multiparametric MRI.
    Int J Urol. 2025;32:1440-1448.
    PubMed     Abstract available
    
    
    September 2025
89. DENIZ ME, Gur G, Kayra MV, Hasbay B, et al
    PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node Metastasis in Prostate Cancer.
    Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
    PubMed     Abstract available
    
    
    
90. MIYOSHI Y, Uemura H, Ohta J, Kobayashi K, et al
    Prognostic Value of BONENAVI Computer-Aided Diagnosis System Bone Scans as an Imaging Biomarker for Bone-Metastatic Castration-Sensitive Prostate Cancer: An Investigator-Initiated, Multicenter, Prospective Observational Study.
    Int J Urol. 2025 Sep 23. doi: 10.1111/iju.70214.
    PubMed     Abstract available
    
    
    
91. HATANO K
    Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".
    Int J Urol. 2025 Sep 17. doi: 10.1111/iju.70236.
    PubMed    
    
    
    
92. NAKAJIMA Y, Hashimoto K, Shindo T, Kobayashi K, et al
    Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 16. doi: 10.1111/iju.70229.
    PubMed    
    
    
    
93. SUZUKI K, Hirata J, Ueki H, Wakita N, et al
    Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.
    Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
    PubMed     Abstract available
    
    
    
94. MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
    Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
    PubMed     Abstract available
    
    
    
95. KAWASE M
    Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
    Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
    PubMed    
    
    
    August 2025
96. ARAI S
    Editorial Comment on Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis.
    Int J Urol. 2025 Aug 21. doi: 10.1111/iju.70208.
    PubMed    
    
    
    
97. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70197.
    PubMed     Abstract available
    
    
    
98. SHIMOMURA T
    Editorial Comment to "Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study".
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70185.
    PubMed    
    
    
    
99. YAMAMOTO Y, Fujimoto S, Hashimoto M, Minami T, et al
    Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70202.
    PubMed     Abstract available
    
    
    
100. YASUDA Y, Wang Z, Yoshida S, Chen W, et al
     Indirect Comparison of PROpel and TALAPRO-2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration-Resistant Prostate Cancer.
     Int J Urol. 2025 Aug 12. doi: 10.1111/iju.70194.
     PubMed    
     
     
     
101. ARAI S
     Editorial Comment on Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
     Int J Urol. 2025 Aug 10. doi: 10.1111/iju.70201.
     PubMed    
     
     
     
102. TOHI Y, Kato T, Fujiwara K, Harada S, et al
     Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
     Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
     PubMed     Abstract available
     
     
     
103. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
     Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
     Int J Urol. 2025;32:982-989.
     PubMed     Abstract available
     
     
     July 2025
104. HIRATA H
     Editorial Comment on "Frontiers of Ultrasound Technology in Prostate Cancer Treatment".
     Int J Urol. 2025 Jul 19. doi: 10.1111/iju.70183.
     PubMed    
     
     
     
105. MITSUI Y, Nakajima K
     Editorial Comment on "Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy".
     Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70166.
     PubMed    
     
     
     June 2025
106. SHOJI S, Takahashi K, Naruse J, Kawamura Y, et al
     Frontiers of Ultrasound Technology in Prostate Cancer Treatment.
     Int J Urol. 2025 Jun 22. doi: 10.1111/iju.70160.
     PubMed     Abstract available
     
     
     
107. TASHIRO K, Mori K, Shiota M, Fukuokaya W, et al
     Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
     Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
     PubMed     Abstract available
     
     
     
108. YASUDA Y, Numao N, Matsumoto S, Tamiya T, et al
     Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
     Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
     PubMed     Abstract available
     
     
     
109. WATANABE R
     Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species".
     Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
     PubMed    
     
     
     
110. OKUDA Y, Kato T, Ishizuya Y, Hayashi T, et al
     PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.
     Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70100.
     PubMed     Abstract available
     
     
     
111. PATTOU M, Neuzillet Y, Ghoneim T, Bosset PO, et al
     Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching.
     Int J Urol. 2025 Jun 4. doi: 10.1111/iju.70142.
     PubMed     Abstract available
     
     
     
112. MA J, Qu X
     VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m(6)A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species.
     Int J Urol. 2025 Jun 3. doi: 10.1111/iju.70140.
     PubMed     Abstract available
     
     
     
113. FALKENBACH F, Penaranda NR, Longoni M, Marmiroli A, et al
     The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy.
     Int J Urol. 2025;32:710-717.
     PubMed     Abstract available
     
     
     
114. KIMURA Y, Honda M, Yamane H, Shimizu R, et al
     Outcomes in Health-Related Quality of Life and Impact of Urinary Incontinence on Health-Related Quality of Life 7 Years After Robot-Assisted Radical Prostatectomy.
     Int J Urol. 2025;32:664-671.
     PubMed     Abstract available
     
     
     May 2025
115. ZHAO X, Sakamoto S, Yamada Y, Sato K, et al
     The Role of Serum Testosterone in the Pathogenesis and Treatment of Prostate Cancer: A Review Based on the Clinical Evidence.
     Int J Urol. 2025 May 23. doi: 10.1111/iju.70125.
     PubMed     Abstract available
     
     
     
116. REIKE MJ, Tully KH, Schulmeier M, Reicherz A, et al
     Functional Outcomes in Patients With Prostate Cancer Undergoing Frozen Section Guided Radical Prostatectomy.
     Int J Urol. 2025 May 20. doi: 10.1111/iju.70115.
     PubMed     Abstract available
     
     
     
117. HATANO K
     Editorial Comment on "Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?".
     Int J Urol. 2025 May 7. doi: 10.1111/iju.70093.
     PubMed    
     
     
     April 2025
118. ROLDAN-TESTILLANO R, Sanchez-Salas R
     Editorial Comment on "Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study".
     Int J Urol. 2025 Apr 25. doi: 10.1111/iju.70083.
     PubMed    
     
     
     
119. NORO T, Utsumi T, Ishitsuka N, Suzuki Y, et al
     Impact of the COVID-19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns.
     Int J Urol. 2025 Apr 24. doi: 10.1111/iju.70085.
     PubMed     Abstract available
     
     
     
120. CHEN W, Yoshida S, Fujii Y
     Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?
     Int J Urol. 2025 Apr 17. doi: 10.1111/iju.70072.
     PubMed    
     
     
     
121. BLAS L, Shiota M, Kato T, Matsumoto R, et al
     Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.
     Int J Urol. 2025 Apr 7. doi: 10.1111/iju.70063.
     PubMed     Abstract available
     
     
     
122. DLAMINI KCS, Coetzee LJ, Mathabe K
     South African single surgeon experience: Comparison of oncological outcomes, robot-assisted radical prostatectomy versus open perineal radical prostatectomy.
     Int J Urol. 2025;32:423-426.
     PubMed     Abstract available
     
     
     
123. FUNAJIMA K, Naito S, Fukai A, Narisawa T, et al
     Urinary continence outcomes after robot-assisted laparoscopic radical prostatectomy: Significance of anterior reconstruction.
     Int J Urol. 2025;32:355-360.
     PubMed     Abstract available
     
     
     
124. KAWAMURA N, Nakayama M, Hayashi T, Nagahara A, et al
     Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.
     Int J Urol. 2025;32:380-386.
     PubMed     Abstract available
     
     
     March 2025
125. YAMAMOTO Y
     Editorial Comments to "Overuse of Imaging in Prostate Cancer Staging".
     Int J Urol. 2025 Mar 24. doi: 10.1111/iju.70021.
     PubMed    
     
     
     
126. SEKINE Y, Fujizuka Y, Nakazawa S, Tsuji Y, et al
     Utility of Combining Prostate Health Index and Magnetic Resonance Imaging for the Diagnosis of Prostate Cancer.
     Int J Urol. 2025 Mar 17. doi: 10.1111/iju.70024.
     PubMed     Abstract available
     
     
     
127. ONISHI K, Nakai Y, Tachibana A, Nishimura N, et al
     Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer.
     Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70018.
     PubMed     Abstract available
     
     
     
128. SEKITO T, Sadahira T
     Editorial Comment on Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose Rate Brachytherapy for Prostate Cancer.
     Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70035.
     PubMed    
     
     
     
129. GUNGE N, Fukuhara Y, Matsuoka W, Fumihiro Y, et al
     Effect of ICG fluorescence-assisted new nerve-sparing of robot-assisted radical prostatectomy on lower urinary tract symptoms.
     Int J Urol. 2025;32:285-292.
     PubMed     Abstract available
     
     
     
130. MITSUI M, Sadahira T, Nagasaki N, Maruyama Y, et al
     Postoperative infections after robotic-assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration.
     Int J Urol. 2025;32:258-263.
     PubMed     Abstract available
     
     
     February 2025
131. MATSUOKA Y
     Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".
     Int J Urol. 2025 Feb 27. doi: 10.1111/iju.70031.
     PubMed    
     
     
     
132. SUZUKI K, Matsuyama H, Matsubara N, Kazama H, et al
     Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.
     Int J Urol. 2025 Feb 25. doi: 10.1111/iju.70019.
     PubMed     Abstract available
     
     
     
133. URABE F, Kimura S
     Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.
     Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70016.
     PubMed    
     
     
     
134. HSIEH PF, Naruse J, Yuzuriha S, Umemoto T, et al
     Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.
     Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013.
     PubMed     Abstract available
     
     
     
135. IWAMOTO H, Izumi K, Mizokami A
     Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.
     Int J Urol. 2025 Feb 17. doi: 10.1111/iju.70015.
     PubMed    
     
     
     
136. TOHI Y, Kato T, Kohashiguchi K, Kaji A, et al
     Overuse of imaging in prostate cancer staging.
     Int J Urol. 2025 Feb 3. doi: 10.1111/iju.70003.
     PubMed     Abstract available
     
     
     
137. HIROSE K, Nakanishi Y, Ogasawara RA, Imasato N, et al
     Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approach.
     Int J Urol. 2025;32:183-189.
     PubMed     Abstract available
     
     
     
138. MINAMI T, Fujimoto S, Fujita K
     Iodine-125 low-dose rate prostate brachytherapy.
     Int J Urol. 2025;32:130-137.
     PubMed     Abstract available
     
     
     January 2025
139. ARAI S
     Editorial Comment on "Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study".
     Int J Urol. 2025 Jan 21. doi: 10.1111/iju.15682.
     PubMed    
     
     
     
140. WASHINO S, Saito K, Yazaki K, Miyagawa T, et al
     A novel anterior approach toward robotic radical prostatectomy is associated with earlier continence recovery than the conventional approach.
     Int J Urol. 2025;32:80-87.
     PubMed     Abstract available
     
     
     
141. KOBAYASHI K, Nofuji S, Okabe K, Yorozuya W, et al
     How do Japanese patients really feel about losing potency after radical prostatectomy? (MAJI study).
     Int J Urol. 2025;32:69-72.
     PubMed     Abstract available
     
     
     
142. TEISHIMA J, Wakita N, Bando Y, Okamura Y, et al
     Effects of modifying hinotori surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.
     Int J Urol. 2025;32:45-50.
     PubMed     Abstract available
     
     
     December 2024
143. CHEN W, Yoshida S, Miura N, Fukuda S, et al
     Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis.
     Int J Urol. 2024 Dec 20. doi: 10.1111/iju.15657.
     PubMed     Abstract available
     
     
     
144. KUMAR V, Jena D, Zahiruddin QS, Roopashree R, et al
     Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).
     Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15641.
     PubMed     Abstract available
     
     
     
145. SUZUKI H, Akamatsu S, Shiota M, Kakiuchi H, et al
     Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
     Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15647.
     PubMed     Abstract available
     
     
     
146. YE DW, Uemura H, Chung BH, Suzuki H, et al
     Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
     Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15615.
     PubMed     Abstract available
     
     
     
147. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
     Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
     Int J Urol. 2024;31:1300-1310.
     PubMed     Abstract available
     
     
     November 2024
148. HAKOZAKI Y, Yamada Y, Fujimura T, Kimura N, et al
     Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy.
     Int J Urol. 2024;31:1241-1247.
     PubMed     Abstract available
     
     
     October 2024
149. OBINATA D, Yamada Y, Sumiyoshi T, Tanegashima T, et al
     Recent advances in basic research on prostate cancer: Where we are heading?
     Int J Urol. 2024 Oct 30. doi: 10.1111/iju.15628.
     PubMed     Abstract available
     
     
     
150. SHIOTA M
     Editorial Comment to Loss of phosphatase and tensin homolog expression in castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
     Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
     PubMed    
     
     
     
151. SATO M, Osawa T, Nishioka K, Miyazaki T, et al
     Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
     Int J Urol. 2024 Oct 9. doi: 10.1111/iju.15602.
     PubMed     Abstract available
     
     
     
152. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
     Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
     Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
     PubMed     Abstract available
     
     
     
153. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
     Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
     Int J Urol. 2024;31:1145-1152.
     PubMed     Abstract available
     
     
     September 2024
154. MITSUI Y, Nakajima K
     Editorial Comment to "Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis".
     Int J Urol. 2024 Sep 26. doi: 10.1111/iju.15582.
     PubMed    
     
     
     
155. GUO X, Zhang F, Hao G
     Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis.
     Int J Urol. 2024 Sep 22. doi: 10.1111/iju.15565.
     PubMed     Abstract available
     
     
     
156. SHIMADA K, Fujiwara M, Hirahara D, Takaya E, et al
     Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging.
     Int J Urol. 2024 Sep 11. doi: 10.1111/iju.15581.
     PubMed    
     
     
     
157. KAMBE T, Yamasaki T, Yamamoto A, Nagoshi A, et al
     Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
     Int J Urol. 2024 Sep 10. doi: 10.1111/iju.15579.
     PubMed     Abstract available
     
     
     
158. KATO T, Tohi Y, Okazoe H, Taoka R, et al
     How widespread is active surveillance of early-stage prostate cancer in Japan? Multicenter questionnaire survey on the status of active surveillance of early-stage prostate cancer in Japan.
     Int J Urol. 2024 Sep 4. doi: 10.1111/iju.15573.
     PubMed    
     
     
     
159. MORITA M, Hiramatsu A, Nishimura K, Yanagida W, et al
     Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
     Int J Urol. 2024;31:1001-1008.
     PubMed     Abstract available
     
     
     
160. COLAKOGLU Y, Eksi M, Ozlu DN, Simsek A, et al
     Comparison of oncological and functional results of robotic and open perineal radical prostatectomy.
     Int J Urol. 2024;31:994-1000.
     PubMed     Abstract available
     
     
     August 2024
161. MATSUOKA Y
     Editorial Comment to "Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?".
     Int J Urol. 2024 Aug 24. doi: 10.1111/iju.15566.
     PubMed    
     
     
     
162. MIURA H, Hatakeyama S, Tabata R, Fujimori D, et al
     Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.
     Int J Urol. 2024 Aug 23. doi: 10.1111/iju.15550.
     PubMed     Abstract available
     
     
     
163. MADENDERE S, Kilic M, Gurses B, Vural M, et al
     Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?
     Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15553.
     PubMed     Abstract available
     
     
     
164. GOTO Y
     Editorial Comment on Japanese clinical practice guidelines for prostate cancer 2023.
     Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15562.
     PubMed    
     
     
     
165. URABE F, Kimura S, Tashiro K
     Is meta-analysis effective in evaluating local treatment benefits for oligometastatic prostate cancer?
     Int J Urol. 2024 Aug 1. doi: 10.1111/iju.15555.
     PubMed    
     
     
     
166. TOHI Y, Osaki Y, Kato T, Honda T, et al
     Impact of the coronavirus disease pandemic on robot-assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study.
     Int J Urol. 2024;31:899-905.
     PubMed     Abstract available
     
     
     July 2024
167. KOHJIMOTO Y, Uemura H, Yoshida M, Hinotsu S, et al
     Japanese clinical practice guidelines for prostate cancer 2023.
     Int J Urol. 2024 Jul 30. doi: 10.1111/iju.15545.
     PubMed     Abstract available
     
     
     
168. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
     Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
     Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
     PubMed     Abstract available
     
     
     
169. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
     Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
     Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
     PubMed     Abstract available
     
     
     
170. SUN Q, Du K, Sun S, Liu Y, et al
     Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
     Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
     PubMed     Abstract available
     
     
     
171. DELLA CORTE M, Checcucci E
     Editorial Comment on "The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery".
     Int J Urol. 2024 Jul 9. doi: 10.1111/iju.15543.
     PubMed    
     
     
     
172. DI BELLO F, Fraia A, Pezone G, Colla Ruvolo C, et al
     The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery.
     Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15516.
     PubMed     Abstract available
     
     
     June 2024
173. SAITO K, Kohada Y, Hieda K, Shikuma H, et al
     Preoperative high serum total testosterone levels predict preserved postoperative sexual function in patients after nerve-sparing robot-assisted radical prostatectomy.
     Int J Urol. 2024 Jun 7. doi: 10.1111/iju.15511.
     PubMed     Abstract available
     
     
     
174. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
     Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
     Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
     PubMed     Abstract available
     
     
     
175. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
     Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
     Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
     PubMed     Abstract available
     
     
     
176. KATO M, Shiota M, Kimura T, Hanazawa R, et al
     Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
     Int J Urol. 2024;31:662-669.
     PubMed     Abstract available
     
     
     May 2024
177. WATANABE H, Nakane K, Takahara K, Naiki T, et al
     Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
     Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
     PubMed     Abstract available
     
     
     
178. URABE F
     The relevance of circRNAs in serum of patients undergoing prostate biopsy.
     Int J Urol. 2024;31:581.
     PubMed    
     
     
     
179. SAMIRAE L, Krausewitz P, Alajati A, Kristiansen G, et al
     The relevance of circRNAs in serum of patients undergoing prostate biopsy.
     Int J Urol. 2024;31:578-580.
     PubMed    
     
     
     
180. CHIARELLI G, Davis M, Stephens A, Cirulli GO, et al
     Comparison of patient background between a real-world North American cohort and the Goteborg-2 trial.
     Int J Urol. 2024;31:562-567.
     PubMed     Abstract available
     
     
     
181. ANDO S, Sugihara T, Hinotsu S, Kishino H, et al
     Early recovery of urinary continence after robot-assisted radical prostatectomy is associated with membranous urethra and neurovascular bundle preservation.
     Int J Urol. 2024;31:492-499.
     PubMed     Abstract available
     
     
     April 2024
182. YAMAMOTO Y, Nonomura N
     Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
     Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
     PubMed    
     
     
     
183. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
     Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
     Int J Urol. 2024;31:404-408.
     PubMed     Abstract available
     
     
     March 2024
184. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
     Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
     PubMed     Abstract available
     
     
     
185. GOTO Y
     Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
     PubMed    
     
     
     
186. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
     Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
     Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
     PubMed     Abstract available
     
     
     
187. GOTO Y
     Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Mar 8. doi: 10.1111/iju.15444.
     PubMed    
     
     
     
188. KAWASE M, Kato D, Tobisawa Y, Iinuma K, et al
     Efficacy and safety of combination neoadjuvant chemo-hormonal therapy and robot-assisted radical prostatectomy for oligometastatic prostate cancer.
     Int J Urol. 2024 Mar 7. doi: 10.1111/iju.15448.
     PubMed    
     
     
     
189. BLAS L, Shiota M, Tanegashima T, Kobayashi S, et al
     Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
     Int J Urol. 2024 Mar 5. doi: 10.1111/iju.15449.
     PubMed    
     
     
     February 2024
190. PARK SJ, Park YJ, Park SM
     Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
     PubMed    
     
     
     
191. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
     Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
     PubMed     Abstract available
     
     
     
192. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
     Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
     PubMed    
     
     
     
193. HIYAMA Y
     Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
     Int J Urol. 2024;31:143.
     PubMed    
     
     
     January 2024
194. SHOJI S
     Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
     PubMed    
     
     
     
195. LIN YH, Chen YT, Tsai HY
     Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
     PubMed    
     
     
     
196. MORI K
     Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
     PubMed    
     
     
     
197. HATANO K
     Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
     Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
     PubMed    
     
     
     
198. UKIMURA O
     Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
     PubMed    
     
     
     
199. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
     Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
     PubMed     Abstract available
     
     
     
200. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
     Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
     PubMed     Abstract available
     
     
     
201. OKANO K, Miyai K, Mikoshi A, Edo H, et al
     Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
     PubMed     Abstract available
     
     
     
202. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
     Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
     Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
     PubMed     Abstract available
     
     
     
203. NAITO Y, Kato M, Nagayama J, Sano Y, et al
     Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
     Int J Urol. 2024;31:7-16.
     PubMed     Abstract available
     
     
     December 2023
204. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
     GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
     Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
     PubMed     Abstract available
     
     
     
205. PARK SJ, Hong J, Park YJ, Jeong S, et al
     Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
     PubMed     Abstract available
     
     
     
206. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
     Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
     Int J Urol. 2023;30:1147-1154.
     PubMed     Abstract available
     
     
     November 2023
207. YUASA T
     Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
     Int J Urol. 2023;30:1034-1035.
     PubMed    
     
     
     
208. SHIRAISHI K
     Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
     Int J Urol. 2023;30:959-967.
     PubMed     Abstract available
     
     
     
209. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
     Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
     Int J Urol. 2023;30:1029-1034.
     PubMed     Abstract available
     
     
     
210. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
     Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
     Int J Urol. 2023;30:1020-1027.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum